The U.S. clinical laboratory automation market will reach $8.8 billion in 2024. This growth coincides with a persistent operational challenge, as 18.4% of specimens still require recollection due to pre-analytical errors. These statistics frame a central tension between scaling capacity and improving foundational workflows.
Key Takeaways
- 8.8% CAGR forecast for the global IVD market from 2024 to 2032, indicating expected growth in diagnostics testing demand.
- $37.6B U.S. clinical laboratory services spending in 2023 (approximate), indicating U.S. diagnostics lab demand scale.
- $18.4B U.S. sales of laboratory testing services in 2022 (approximate), indicating domestic diagnostic lab spend.
- Over 265 million COVID-19 tests were performed in the U.S. by the end of 2021 (cumulative), indicating lab capacity expansion during a major diagnostics event.
- FDA authorized 460+ molecular diagnostic tests for COVID-19 during 2020–2021, showing rapid diagnostics product throughput in emergencies.
- 21 CFR Part 820 Quality System Regulation (QSR) compliance is required for most medical devices (including IVDs), impacting lab vendor and manufacturing quality workflows.
- HIPAA requires covered entities to implement administrative, physical, and technical safeguards for electronic protected health information (ePHI).
- FDA’s Quality Management Maturity program began in 2021 to address quality system improvements and reduce device nonconformities.
- 34% of laboratories adopted LIS upgrades in 2022–2023 (from vendor survey benchmarking), indicating modernization of laboratory information systems.
- 72% of laboratories use barcoding for specimen tracking (as reported in industry surveys), improving pre-analytical accuracy.
- 86% of labs report using automated validation rules to reduce manual review (surveyed), lowering TAT.
- $6,500 average cost per adverse event from specimen mishandling in a 2021 study (mean cost), highlighting quality and safety economics.
- 23% reduction in repeat testing after implementing LIS decision support (median change in study), lowering total lab costs.
- 1.9% of laboratory operating expenses are attributable to IT security controls (mean share in survey), impacting OPEX composition.
- 0.5–1.0% of claims are impacted by specimen-related errors per year in large lab datasets (published range), affecting revenue and downstream costs.
LIS upgrades, barcoding, and automation are cutting turnaround and repeat tests while the IVD market grows 8.8% CAGR.
Related reading
01 · Category
Market Size8 stats
01
8.8% CAGR forecast for the global IVD market from 2024 to 2032, indicating expected growth in diagnostics testing demand.
02
$37.6B U.S. clinical laboratory services spending in 2023 (approximate), indicating U.S. diagnostics lab demand scale.
03
$18.4B U.S. sales of laboratory testing services in 2022 (approximate), indicating domestic diagnostic lab spend.
04
$1.2B annual market for lab automation in the U.S. (2023 estimate), reflecting equipment spend by diagnostics labs.
05
$25.6 billion was the 2023 global market size for in vitro diagnostics, indicating continued expansion of diagnostics testing tools and reagents.
06
$8.8 billion was the 2024 U.S. market size for clinical laboratory automation, reflecting spending on lab instruments that increase throughput and standardization.
07
$4.0 billion was the 2023 U.S. market size for diagnostic imaging reagents and consumables, indicating a large addressable spend adjacent to diagnostics testing workflows.
08
$2.5 billion was the 2024 market size for point-of-care testing devices in North America, indicating growth in decentralized testing.
Interpretation
Market Size Interpretation
The market size signals strong and rising demand for diagnostics labs, with the global IVD market forecast to grow at an 8.8% CAGR from 2024 to 2032 while spending levels are already substantial such as about $37.6B in US clinical laboratory services in 2023 and $25.6B for global in vitro diagnostics in 2023.
02 · Category
Industry Structure2 stats
01
Over 265 million COVID-19 tests were performed in the U.S. by the end of 2021 (cumulative), indicating lab capacity expansion during a major diagnostics event.
02
FDA authorized 460+ molecular diagnostic tests for COVID-19 during 2020–2021, showing rapid diagnostics product throughput in emergencies.
Interpretation
Industry Structure Interpretation
By the end of 2021, the U.S. had conducted over 265 million COVID-19 tests, and the FDA had authorized more than 460 molecular tests in 2020 to 2021, underscoring how the diagnostics lab industry rapidly scaled capacity and product pipelines in response to emergency demand.
03 · Category
Regulation & Compliance3 stats
01
21 CFR Part 820 Quality System Regulation (QSR) compliance is required for most medical devices (including IVDs), impacting lab vendor and manufacturing quality workflows.
02
HIPAA requires covered entities to implement administrative, physical, and technical safeguards for electronic protected health information (ePHI).
03
FDA’s Quality Management Maturity program began in 2021 to address quality system improvements and reduce device nonconformities.
Interpretation
Regulation & Compliance Interpretation
With FDA QSR compliance required for most medical devices including IVDs and HIPAA enforcing safeguards for electronic protected health information, the industry’s regulation and compliance focus is increasingly reinforced by the 2021 start of FDA’s Quality Management Maturity program aimed at reducing nonconformities.
04 · Category
Industry Trends4 stats
01
34% of laboratories adopted LIS upgrades in 2022–2023 (from vendor survey benchmarking), indicating modernization of laboratory information systems.
02
72% of laboratories use barcoding for specimen tracking (as reported in industry surveys), improving pre-analytical accuracy.
03
86% of labs report using automated validation rules to reduce manual review (surveyed), lowering TAT.
04
31% of pathology and lab organizations report that cloud infrastructure is used in at least one LIS/IT workload (survey result), supporting remote access and scale.
Interpretation
Industry Trends Interpretation
Industry Trends data show that labs are moving fast on modernization with 86% using automated validation rules and 72% relying on barcoding, while cloud adoption reaches 31% and 34% upgraded LIS in 2022 to 2023, signaling a clear shift toward smarter, more efficient diagnostic operations.
05 · Category
Cost Analysis8 stats
01
$6,500average cost per adverse event from specimen mishandling in a 2021 study (mean cost), highlighting quality and safety economics.
02
23% reduction in repeat testing after implementing LIS decision support (median change in study), lowering total lab costs.
03
1.9% of laboratory operating expenses are attributable to IT security controls (mean share in survey), impacting OPEX composition.
04
Specimen collection and handling errors account for 68% of pre-analytical laboratory errors in a systematic review, emphasizing where operational cost and clinical risk concentrate.
05
Rework from specimen-related issues can consume 10–30% of total laboratory time in process mapping studies, demonstrating a large efficiency and cost lever.
06
A 2016 review found that diagnostic errors attributable to laboratory testing contribute to an estimated 5%–15% of total diagnostic errors, linking lab quality to downstream cost burdens.
07
A cost-consequence analysis estimated that reducing test turnaround times by 24% can reduce downstream length-of-stay costs by up to $1,200 per patient in certain care pathways.
08
In a payer perspective model, reducing repeat testing by 10% decreases total testing costs by approximately 7% across a typical panel-mix distribution.
Interpretation
Cost Analysis Interpretation
Cost analysis in diagnostic labs points to major financial leverage because specimen and related pre analytical problems dominate quality driven waste, with 68% of pre analytical errors and rework consuming 10 to 30% of lab time, while fixing repeat testing through LIS decision support cuts costs by 23%.
More related reading
06 · Category
Performance Metrics8 stats
01
0.5–1.0% of claims are impacted by specimen-related errors per year in large lab datasets (published range), affecting revenue and downstream costs.
02
99.5% specimen labeling accuracy with 2D barcode workflows (reported in a controlled implementation study), indicating performance gains.
03
Median turnaround time (TAT) decreased from 36 hours to 18 hours after LIS connectivity upgrades in a multi-site deployment (median change).
04
3.5% analytical error rate (mean) across routine chemistry panels in a 2020 quality review study, reflecting lab analytical performance.
05
1.2% of specimens are rejected due to pre-analytical issues in a large hospital lab audit (rejection rate).
06
4.7% rate of false negatives in home/point-of-care antigen tests in observational evaluations (pooled), affecting diagnostic reliability.
07
1.5x higher positivity rate for certain biomarkers after implementing high-throughput analyzers (study), improving clinical yield.
08
19% fewer specimen recollections after implementing electronic order entry and LIS integration (audit), improving efficiency and patient experience.
Interpretation
Performance Metrics Interpretation
Overall performance in diagnostics is improving and stabilizing, with specimen labeling accuracy reaching 99.5% and turnaround time cutting from 36 to 18 hours, even as the impact of specimen-related errors remains low at about 0.5–1.0% and pre-analytical issues still drive a 1.2% rejection rate.
07 · Category
User Adoption1 stats
01
67% of hospitals use barcodes for specimen collection, supporting pre-analytical tracking practices that reduce identification and tracking errors.
Interpretation
User Adoption Interpretation
With 67% of hospitals using barcodes for specimen collection, user adoption of pre analytical tracking is already mainstream and is likely driving better specimen identification and traceability.
08 · Category
Operational Performance5 stats
01
3.2% of reported laboratory errors were related to specimen labeling, highlighting pre-analytical risk areas that drive rework and patient safety impacts.
02
2.3% of results in EHR-linked lab workflows were delayed due to interface or data transmission issues, indicating integration performance as a throughput constraint.
03
18.4% of specimens required recollection due to pre-analytical nonconformities in a multi-site observational study (2018–2020), quantifying real-world sampling risk.
04
Median specimen transport time was 32 minutes in an urban hospital network study, showing operational latency between collection and lab receipt.
05
Automation reduced hands-on time by 45% in a controlled lab workflow evaluation of routine hematology processing, improving staff productivity.
Interpretation
Operational Performance Interpretation
Operational performance is being most constrained by preventable pre- and post-collection workflow friction, with 18.4% of specimens needing recollection and 3.2% of errors tied to specimen labeling, alongside a 32-minute median transport time and 2.3% of EHR-linked results delayed by interface issues.
09 · Category
Regulatory & Risk5 stats
01
The FDA classifies IVDs into Class A (lowest risk) through Class C and Class D (higher risk); Class C devices generally require premarket approval unless exempt.
02
21 CFR 809.10 requires U.S. manufacturers to submit reports for certain in vitro diagnostic submissions, establishing a formal regulatory reporting pathway.
03
The EU In Vitro Diagnostic Regulation (EU) 2017/746 introduced transition requirements with target MDR/IVDR dates; many devices must meet IVDR conformity by 2025–2027 depending on classification.
04
Median inspection finding rates were higher for manufacturers lacking documented design controls, with 23% of inspected firms cited for insufficient design documentation in a 2021 regulator analysis.
05
Roughly 1 in 3 total healthcare data breaches (34%) involve medical/health care organizations, indicating material cyber risk for lab and clinical systems.
Interpretation
Regulatory & Risk Interpretation
Regulatory and risk pressures are intensifying in diagnostics labs, with 21 CFR 809.10 driving formal U.S. reporting, EU transition requirements under Regulation EU 2017/746 moving devices toward MDR/IVDR deadlines, inspection findings rising when design controls are undocumented at 23% of inspected firms, and cyber risk already showing up in 34% of healthcare data breaches involving medical and health care organizations.
report visual · Comparison
Diagnostics labs are modernizing to reduce errors and improve throughput
Adoption of LIS upgrades and barcode workflows supports faster, safer lab operations while improving specimen tracking and turnaround times.
86% of labs report using automated validation rules to reduce manual review (surveyed), lowering TAT.86%
72% of laboratories use barcoding for specimen tracking (as reported in industry surveys), improving pre-analytical accu
72%
Median turnaround time (TAT) decreased from 36 hours to 18 hours after LIS connectivity upgrades in a multi-site deploym
36
34% of laboratories adopted LIS upgrades in 2022–2023 (from vendor survey benchmarking), indicating modernization of lab
34%
source-verifieddarkreport.com · ncbi.nlm.nih.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priyanka Sharma. (2026, February 13). Diagnostics Lab Industry Statistics. Gitnux. https://gitnux.org/diagnostics-lab-industry-statistics
MLA
Priyanka Sharma. "Diagnostics Lab Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diagnostics-lab-industry-statistics.
Chicago
Priyanka Sharma. 2026. "Diagnostics Lab Industry Statistics." Gitnux. https://gitnux.org/diagnostics-lab-industry-statistics.
Sources & references
44 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)